Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
United Therapeutics Corporation currently has 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 9 distinct examiners, meaning no single examiner is handling more than a case for the company. The prosecution activity is situated within 6 distinct art units, which indicates that even with a small number of 9 pending actions, the company's research is spread across several specialized administrative groups at the patent office.
REILLY, SOPHIA JANE is identified as the busiest examiner, though she is only responsible for 1 pending office action. This reflects the total dispersion of the pending actions across the 9 distinct examiners. The presence of 6 distinct art units for the pending actions suggests a diverse set of pharmaceutical or biotechnological innovations that do not cluster heavily in a single specialized group. For practitioners, this means that prosecution strategies must be developed on a case-by-case basis, as there is no opportunity to leverage experience with a specific examiner or a single dominant art unit. The busiest examiner is responsible for 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18586056 | TREATMENT FOR INTERSTITIAL LUNG DISEASE | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17164693 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY | MARTIN, PAUL C | 13d |
| 18416389 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | MOU, LIYUAN | — |
| 18147929 | ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL | SCHUBERG, LAURA J | — |
| 17894709 | METHOD TO OBTAIN CELLS FROM LUNG TISSUE | JOHNSON, ALLISON MARIE | — |
| 17003431 | METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17164693 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY | MARTIN, PAUL C | 13d |
| 19348278 | RALINEPAG PRODRUGS AND USES THEREOF | REILLY, SOPHIA JANE | — |
| 18416389 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | MOU, LIYUAN | — |
| 18106782 | TREPROSTINIL ILOPROST COMBINATION THERAPY | ARMSTRONG, SUSANNAH SIPPLE | — |
| 18147929 | ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL | SCHUBERG, LAURA J | — |
| 17894709 | METHOD TO OBTAIN CELLS FROM LUNG TISSUE | JOHNSON, ALLISON MARIE | — |
| 17003431 | METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS | GONZALES, JOSEPHINE MARIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1627 | 1 |
| 1628 | 1 |
| 1616 | 1 |
| 1638 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19348278 | RALINEPAG PRODRUGS AND USES THEREOF | REILLY, SOPHIA JANE | 1627 | §103 | Non-Final OA | — | Pending | Oct 02, 2025 |
| 18586056 | TREATMENT FOR INTERSTITIAL LUNG DISEASE | WARD, PAUL V | — | DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18416389 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | MOU, LIYUAN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18106782 | TREPROSTINIL ILOPROST COMBINATION THERAPY | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103DP | Non-Final OA | — | Pending | Feb 07, 2023 |
| 18147929 | ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL | SCHUBERG, LAURA J | 1631 | §102§103§112DP | Non-Final OA | — | Pending | Dec 29, 2022 |
| 17894709 | METHOD TO OBTAIN CELLS FROM LUNG TISSUE | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17164693 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY | MARTIN, PAUL C | 1653 | §102§103§112 | Non-Final OA | 13d | Pending | Feb 01, 2021 |
| 17003431 | METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS | GONZALES, JOSEPHINE MARIA | 1631 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial